MAY 11, 2017
Novaliq has announced a collaboration with the University of Cologne to develop a first-in-class treatment for ocular neuropathic pain and inflammation in individuals with dry eye disease (DED).
The novel therapeutic approach will utilize Novaliq’s semifluorinated alkane technology called EyeSol, which allows for a preservative-free, multidose preparation that’s more comfortable for the patient.
The collaboration will attempt to exploit the cannabinoid receptor, which is well known for neuroprotective and pain-inhibiting properties. However, various molecules targeting these receptors are unstable in water-based formulations and undergo fast autoxidation. The company believes that the EyeSol technology will enhance its topical bioavailability, stability and efficacy.
“Increasing evidence is available on the importance of neuropathic ocular pain in DED. Based on solid results of our ongoing test series we expect a significant impact of Novaliq’s first-in class Nov-07 program in comparison with existing DED drugs on an established DED mouse model,” said Professor Philipp Steven, MD, at the department of ophthalmology, University of Cologne, Germany. “We are now translating evidence from our experimental model into final, conformational studies in close cooperation with Novaliq for a Phase I clinical study in the near future. Based on the preclinical results, we believe that the Nov-07 program will facilitate the treatment of DED utilizing a dual mode of action towards inflammation and ocular neuropathic pain.”
This drug will be the third investigational dry eye therapy to use the EyeSol technology. Novaliq previously announced positive phase 2 results for an Eyesol-based cyclosporine product, which showed improved corneal staining along with excellent safety, tolerability and comfort among 207 patients. EyeSol therapies for glaucoma and retinal diseases are also in early-stage development.